1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

How NGM Bio Intends To Build An Old-School Biotech

 
• By Mike Ward

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.

Video interview
NGM Bio's Jeff Jonker talks NASH

With the hepatitis C challenge broadly solved, the leading cause of expensive liver transplants is now a disease called non-alcoholic steatohepatitis (NASH), which, not surprisingly, is attracting a lot of attention from companies looking to develop treatments.

Jeff Jonker, president of NGM Biopharmaceuticals Inc., a San Francisco-based biotech, explains to Scrip how he is positioning its lead Phase II asset, NGM282, in what is a very...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.